Can nitroglycerin be used to treat a patient who has had a myocardial infarction and is currently in ventricular fibrillation (VF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, Nitroglycerin Should NOT Be Given During Active Ventricular Fibrillation

If a patient is in ventricular fibrillation (V-fib), nitroglycerin has absolutely no role and should not be administered—the immediate priority is defibrillation and advanced cardiac life support (ACLS) protocols. V-fib is a pulseless cardiac arrest rhythm requiring immediate electrical defibrillation, high-quality CPR, and epinephrine per ACLS guidelines. Nitroglycerin is a vasodilator used for ischemic chest pain and hemodynamic management, not for treating lethal arrhythmias.

Critical Context: When Nitroglycerin IS Appropriate in MI

Nitroglycerin has well-established benefits in myocardial infarction, but only in hemodynamically stable patients with perfusing rhythms:

Appropriate Use in MI (When NOT in V-fib):

  • Ischemic chest pain relief: Patients with ongoing ischemic pain should receive sublingual nitroglycerin (up to 3 doses at 3-5 minute intervals) unless systolic blood pressure is <90 mmHg 1
  • Hemodynamic support: IV nitroglycerin is indicated for congestive heart failure complicating acute MI and for peri-operative hypertension 2
  • Potential mortality benefit: Some evidence suggests IV nitroglycerin may reduce infarct size and decrease susceptibility to ventricular fibrillation during ischemia and reperfusion 3

Absolute Contraindications for Nitroglycerin:

Nitroglycerin should be avoided when 1:

  • Systolic blood pressure <90 mmHg or ≥30 mmHg below baseline
  • Extreme bradycardia (<50 bpm) or tachycardia (>100 bpm) without heart failure
  • Right ventricular infarction (extreme caution or avoid entirely)
  • Pulseless cardiac arrest rhythms including V-fib (not explicitly stated but clinically obvious—no perfusion means no drug delivery)

The Clinical Algorithm:

Step 1: Is the patient in cardiac arrest (V-fib, pulseless V-tach, asystole, PEA)?

  • YES → Follow ACLS: Immediate defibrillation, CPR, epinephrine, consider amiodarone. NO nitroglycerin.
  • NO → Proceed to Step 2

Step 2: Does the patient have a perfusing rhythm with ongoing ischemic chest pain?

  • Check blood pressure, heart rate, and assess for right ventricular involvement (especially with inferior MI)
  • If SBP ≥90 mmHg and no marked bradycardia/tachycardia → Sublingual nitroglycerin appropriate 3, 1

Step 3: After return of spontaneous circulation (ROSC) from V-fib:

  • Once hemodynamically stable with adequate blood pressure, nitroglycerin may be considered for ongoing ischemia or heart failure
  • Titrate carefully with frequent vital sign monitoring 3

Important Caveats:

While one case report 4 describes successful resuscitation using IV nitroglycerin during V-fib arrest secondary to coronary vasospasm from misoprostol, this represents an exceptional circumstance with a specific reversible cause. This single case does not change standard ACLS protocols—defibrillation remains the definitive treatment for V-fib.

The evidence showing nitroglycerin may decrease susceptibility to ventricular fibrillation 3, 5 refers to prevention during ischemia and reperfusion in patients with perfusing rhythms, not treatment of established V-fib arrest.

The most serious potential complication of nitroglycerin in MI is inadvertent systemic hypotension, which worsens myocardial ischemia 3. In a pulseless patient, this concern becomes moot—there is no blood pressure to drop because there is no cardiac output. The priority is restoring a perfusing rhythm through defibrillation and ACLS.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.